
    
      The purpose of this study is to evaluate the safety, efficacy and pharmacokinetic (PK)
      parameters of plecanatide of once daily oral 4 dose levels of plecanatide (0.5, 1.0, 2.0, or
      3.0 mg) for 4 weeks as treatment in children 6 to <18 years of age with IBS-C.

      The study will include a 28-day Screening/Baseline Period, a 4 week treatment period, and a
      2-week post-treatment follow-up period. Patients/caregivers will visit the clinic 4 times
      during the study.
    
  